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Layered double hydroxide (LDH) is an inorganic–organic nano-layered material that harbours drug between its
two-layered sheets, forming a sandwich-like structure. It is attracting a great deal of attention as an alternative drug
delivery (nanodelivery) system in the field of pharmacology due to their relative low toxic potential. The production
of these nanodelivery systems, aimed at improving human health through decrease toxicity, targeted delivery
of the active compound to areas of interest with sustained release ability. In this study, we administered
zinc-aluminium-LDH-levodopa nanocomposite (ZAL) and zinc-aluminium nanocomposite (ZA) to Sprague Dawley
rats to evaluate for acute oral toxicity following OECD guidelines. The oral administration of ZAL and ZA at a limit
dose of 2,000 mg/kg produced neither mortality nor acute toxic signs throughout 14 days of the observation. The
percentage of body weight gain of the animals showed no significant difference between control and treatment
groups. Animal from the two treated groups gained weight continuously over the study period, which was shown
to be significantly higher than the weight at the beginning of the study (P < 0.05). Biochemical analysis of animal
serum showed no significant difference between rats treated with ZAL, ZA and controls. There was no gross
lesion or histopathological changes observed in vital organs of the rats. The results suggested that ZAL and ZA at
2,000 mg/kg body weight in rats do not induce acute toxicity in the animals. Elemental analysis of tissues of treated
animals demonstrated the wider distribution of the nanocomposite including the brain. In summary, findings
of acute toxicity tests in this study suggest that zinc-aluminium nanocomposite intercalated with and the
un-intercalated were safe when administered orally in animal models for short periods of time. It also highlighted
the potential distribution ability of Tween-80 coated nanocomposite after oral administration.
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Levodopa is still the gold standard in symptomatic treat-
ment of Parkinson’s disease (PD), though there are many
therapeutic options and the list kept on expanding tre-
mendously, all with the view to improve on PD manage-
ment [1]. A major therapeutic challenge and controversy
in the usage of levodopa is its potential to cause toxic ef-
fects on nigrostriatal cells. This will potentiate the pro-
gression of neurodegeneration and ultimately worsening
of Parkinson’s disease symptoms [1]. There is no direct
evidence showing levodopa causing toxicity in PD* Correspondence: sharida@upm.edu.my
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in any medium, provided the original work is ppatient, but there are increasing cell and animal study
evidence of such [1]. This is adding to the panic and
worries of possible neurotoxicity in human being [1].
Levodopa has the ability to potentiate free radical pro-
ductions [1], which are known to be toxic to cells. An-
other setback with levodopa usage is its potential to
cause long-term adverse effects of dyskinesia and other
motor fluctuations. These side effects were believed to
be due to pulsatile stimulation of the dopaminergic
neuron at the substantia nigra by levodopa leading to
‘off and on’ excitation of the neurons [1].
Layered double hydroxide (LDH) compounds of magne-
sium and aluminium ions are attracting a great deal of at-
tention, as alternative drug delivery system in the field of
pharmacology [2-4]. This is due to their low toxicity po-
tential compared to the other nanodelivery systems [2,5].Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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tween two layered sheets, forming a sandwich-like struc-
ture [3]. Drug release by this noble carrier follows the
principle of ion exchange that governs drug intercalation
during synthesis, especially in lower acidic environment,
while burst release is seen in an acidic environment [2,3].
Surrounding anions such as Cl− and/or phosphate ex-
changes for the anionic drug intercalated between the
nanosheets [4,6]. Treatment of peptic ulcer diseases
using LDH nano-carrier as oral antacids and anti-
pepsin is a clear attestation to the established safety
and biocompatibility of this nanodelivery system [7].
Among the different types of inorganic nanodelivery
systems, LDH of either aluminium or magnesium is
shown to be the least toxic [5], making it a widely used
alternative drug delivery system containing different
type of drugs, genes and proteins [3,4].
Nanodelivery systems are generally aimed at improv-
ing human health through decreased toxicity, targeted
delivery of the active compound to areas of interest and
sustained release. Nevertheless, of concern is the toxicity
of some of the nanodelivery systems, which could be
from the material used, the synthetic process, the drug
intercalated, the coating agent, the particle size, the dis-
tribution pattern and the end products of the delivery
system [3,8,9]. Thus, comprehensive assessment of any
newly synthesized nanomaterial is inevitable, although
in vivo tests are supposed to be replaced by in vitro as-
sessment due to time-consuming, cost and related eth-
ical issues. However, in vivo toxicity assessment is still
recommended due to the complexity of the body system,
which may influence the pharmacokinetics of nanodeliv-
ery system, hitherto not seen during an in vitro toxicity
tests, and vice versa. This will give valuable inputs in the
real-life system.
Pharmaceutical formulations including nanodelivery
systems (NDSs) are taken into the human body through
any of the several routes of drug administration [10,11].
The route of exposure may influence the distribution
and bioavailability, especially transport across biological
barriers like the brain [11]. Oral route in drug adminis-
tration is perhaps the most preferred by the patient and
the clinician alike; it is the most convenient, cost effect-
ive and relatively easier to use [12]. Thus, it has the
highest level of patient compliance, although it is not
without some limitation. Among the various limitations
of oral route for drug delivery are hepatic first pass me-
tabolism and enzymatic degradation within the gastro-
intestinal tract [13]. These factors are prohibiting oral
administration of certain classes of drugs, especially pro-
teins and the peptides [14]. Consequently, parenteral
routes like intravenous, intramuscular and subcutaneous
routes of administration are resorted to deliver some
agents [2,3]. Nanotechnology base-drug delivery systemsare now offering many advantages over the conventional
system. They have good drug intracellular penetration
and enhanced absorption into targeted tissues, even
where orally administered. They also show better phar-
macokinetic (PK) properties, increased clinical efficacy
and reduced toxicity in most cases [15].
Surface coating of nanodelivery systems with linkers
like chitosan, polyethylene glycol (PEG), polysorbate-80
(Tween-80), polyvinyl alcohol (PVA) or polysaccharide
can prevent aggregation, enhance solubility, minimize
nonspecific binding, prolong circulation time and at
times serve as a specific tissue-targeting mechanism
[16]. Thus, given a nanodelivery system, better distribu-
tion increases serum half-life and wider application
both in parenteral and nonparenteral administration.
The presence of the blood–brain barrier (BBB) is affect-
ing treatment of brain pathologies with the conventional
and most nanodelivery systems. The barrier excludes com-
pounds from reaching the brain in the desired concentra-
tion, thus limiting the expected therapeutic effect in many
central nervous system (CNS) diseases [17]. A very prom-
ising approach in overcoming this obstacle is the use of
the nanodelivery system especially after surface modifica-
tion with polymers or surfactants [18]. Tween-80 coating
of nanoparticle was reported to be helpful in delivering
drugs to the brain [19,20]. Materials coated with this
surfactant were capable of transporting loaded drugs
across the BBB after oral and intravenous administra-
tion. Apolipo-protein-B acquisition on the surface of
this material was shown to be the mediator behind this
success, where the acquired protein is transported via
LDH receptors located at the endothelium of the BBB
[19]. Then, the active drug loaded on the nanodelivery
system will be released inside the brain.
Nanomaterial’s size is also crucial in determining nano-
particle distribution; the reticule endothelial systems, not-
ably in the liver, spleen and kidney, were implicated in
sequestrating larger percentage of these materials within
the range of 100 to 250 nm [21]. Nevertheless, surface
modification was reported to alter these facts; for example,
a layered double hydroxide nanocomposite with diameter
size of 100 to 200 nm coated with chitosan showed a pref-
erence in distribution to the liver, lung, spleen and kidney
[22]. Delivery of the same nanocomposite to the lung, but
not the liver, kidney or spleen, was achieved through fur-
ther addition of more chitosan [22]. This preferential dis-
tribution of the nanomaterial following addition of coating
substance is attributed to better solubility, lesser aggrega-
tion and improved dispersion.
Our previous studies provided detail synthesis, surface
coating and characterization of zinc-aluminium-levodopa
nanocomposite (ZAL), a nanodelivery system for the treat-
ment of Parkinson’s disease [3,23]. Briefly, zinc and alu-
minium molar ratio of 2:1 were used via co-precipitation
Table 1 Arrangement of rats into different groups
Groups Dose (concentration) Number of rats
ZAL 2,000 mg/kg 7
ZA 2,000 mg/kg 7
VC 100 mL/kg (body weight) 7
A table showing grouping arrangement and doses of nanocomposite given to
animals (n= 7) ZAL (zinc-aluminium-levodopa nanocomposite), ZA (zinc-aluminium
nanocomposite) and VC (vehicle control).
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was demonstrated using X-ray diffraction and Fourier
transform infrared spectroscopy (FTIR), in which the new
delivery system contains about 16% levodopa by weight. It
was shown to gain added thermal stability and exhibited a
sustained, continuous and controlled levodopa release
from the two pH value tested [3]. Toxicity result using the
nanodelivery technique on cell line in the same study was
demonstrated to be reduced compared to pure levodopa.
Further coating of ZAL with polysorbate-80 (Tween-80)
showed an improved release profile and a better cell viabil-
ity ([23]. Repeated dose of the same nanocomposite in ani-
mal study showed slight liver and renal derangement [10].
However, establishing the entire toxicological profile using
an animal model, acute and chronic toxicity assessment is
also indispensable.
In this study, the acute oral toxicity and distribution
potentials of Tween-80-coated zinc-aluminium-levodopa
nanocomposite were evaluated according to the fixed
dose procedures (OECD, 2002) [24]. Changes in coeffi-
cients of tissues to body weight, gross and histopatho-
logical deviations, as well as alteration in biochemical
parameters such as liver and renal enzymes, were
assessed. Synthesis of ZAL was aimed to provide an al-
ternative to Parkinson’s disease treatment strategy. Thus,
providing complete information on the safety of this lay-
ered hydroxide nanocomposite in drug delivery is the
primary objective of this study.
Methods
Animals
Male Sprague Dawley rats were 6 to 8 weeks old; average
weight of 200 ± 20 g were obtained from in-house animal
facility and used as experimental animals. The rats were
housed in plastic cages, three rats per cage, and main-
tained in the animal house of the Department of Human
Anatomy, Faculty of Medicine and Health Sciences
Universiti Putra Malaysia. They were maintained under
standard conditions of temperature 25°C ± 2°C, relative
humidity 70% ± 5% and 12-h light–dark cycle. Feeding of
the animals and water intake were done with standard rat
pellets and tap water ad libitum throughout the experi-
ments. In general, animal handling, from the beginning to
the end of the study, was ethically done according to the
agreed guidelines for the university, Universiti Putra
Malaysia Institutional Animal Care and Use Committee
(IACUC) [25].
Acute oral toxicity test in rats
Animals were kept for 5 days to allow for acclimatization
to the laboratory conditions before commencement of the
study. A single (1 day) oral dose of the drugs was given as
per the Organization for Economic Co-operation and
Development (OECD) 407 guidelines (OECD, 2002) [12].Twenty-one animals were distributed randomly into three
groups (Table 1): group 1, zinc-aluminium-levodopa nano-
composite (ZAL 2,000 mg/kg); group 2, zinc-aluminium
nanocomposite (ZA 2,000 mg/kg); group 3, vehicle control
(normal saline 100 mL/kg) body weight (Table 1).
A freshly prepared nanocomposite was given to each rat
in treatment groups, while the rats in the control group re-
ceived only normal saline. At the beginning of the study
(marked as day 0), the weight of animals was recorded,
thereafter the body weight was recorded at day 7 and lastly
on day 14 just before the sacrifice. Animals were monitored
at intervals of 30 min, 1 h, 2 h, 4 h and 12 h on the first
day and subsequently twice daily during the course of
treatment, observing for any clinical signs of toxicity and
possible mortality. At the end of 14 days of observation,
animals were sacrificed via exsanguination through cardiac
puncture following anaesthesia with ketamine and xylazine
at a dose of 80 and 10 mg/kg, respectively. The brain, liver,
spleen, heart and kidney were harvested, weighed and
macroscopically examined for lesions and/or abnormalities.
Coefficients of the brain, liver, spleen, heart and kidney
The coefficients of these organs, the brain, liver, spleen,
heart and kidney, were calculated as the ratio of the or-
gans to body weight [the ratio of organ (wet weight, mg)
to body weight (g)].
Biochemical analysis
Blood taken was placed in a plain 2 mL Eppendorf tube
and allowed to stand for about 30 min before it was
centrifuged at 1,500 rpm for 5 min (Eppendorf 5810R,
Hamburg, Germany), at room temperature; the serum
obtained was used for urea, sodium, potassium, creatin-
ine, chloride, AST, ALT and GGT using a diagnostic kits
(Roche, Basel, Switzerland) in an automatic biochemistry
analyser (Hitachi 902, Tokyo, Japan).
Histopathological evaluation
Postmortem examination was conducted immediately after
sacrifice to detect the presence of any abnormality on the
animal’s vital organs. The gross appearance of these organs
was observed with the naked eye, while the histological
appearance of the liver, spleen, kidney and brain were
observed after haematoxylin-eosin (H&E) stain. The ani-
mals were subjected to trans-cardiac perfusion using 4%
Table 2 Animal grouping for distribution study
Groups Dose (concentration) Number of rats
ZAL 2,000 mg/kg (single dose) 7
500 mg/kg (repeated doses) 7
5 mg/kg (repeated doses) 7
VC 100 mL/kg (body weight) 7
A table showing grouping arrangement and doses of nanocomposite given to
animals (n = 7) ZAL (zinc-aluminium-levodopa nanocomposite), ZA (zinc-aluminium
nanocomposite) and VC (vehicle control).
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later subjected to standard tissue processing and were
embedded in paraffin blocks. The tissues were micro-
sectioned into 5 μm thickness and mounted onto glass
slides. The H&E staining technique was used to stain
the slides, and they were viewed using an optical
microscope (Olympus FSX-100, Olympus Corporation,
Shinjiku-ku, Tokyo, Japan).
Nanocomposite size, particle distribution and tissue
distribution
The particle size distribution was determined for the
levodopa-loaded and unloaded nanocomposite before
and after coating with Tween-80. This is to compare and
to assess the impact of Tween-80 coating on the nano-
composite. The sizes were obtained by measuring the di-
ameters of about 80 nanocomposites randomly through
the TEM images, and the results were analysed using
UTHSCSA Image Tool software.
The distribution analysis of Tween-80-coated zinc-
aluminium-levodopa nanocomposite was studied from
the tissues obtained from rats treated with nanocompos-
ite and control groups. The tissues were obtained from
the above-mentioned animal groups as well from our
previous sub-acute toxicity study of the same com-
pounds (Table 2) [10]. Tissues of the liver, spleen, kidney
and brain were taken out and thawed. From each organ,
about 0.3 g of the tissue were collected, weighed,
digested and analysed for zinc. Tissue digestion was
done as previously described for titanium analysis from
mice organs [5]. In brief, equal amount (about 0.3 g) of
tissues from each of the above-mentioned organs and
500 μl from serum were digested in a mixture of nitric
acid (ultrapure grade) and H2O2 at ratio 6:1. The mix-
ture was heated at about 160°C using high-pressureTable 3 Morbidity and mortality data of experimental rats
Groups Dose (concentration) Toxicity sign
ZAL 2,000 mg/kg 0/7
ZA 2,000 mg/kg 0/7
VC 100 mL/kg 0/7
Table showing morbidity and mortality data after a single high dose (2,000 mg/kg)
control group. Based on the dose used, no rats showed any sign of clinical toxicity,
studied. Data are expressed as mean ± SD, n = 7. t/n toxic/normal, d/a dead/alive, l/nreaction container in an oven chamber until the samples
were completely digested. Then, the high-pressure con-
tainers were let loose and the remaining solution heated
at 120°C until the solution was colourless and the
remaining nitric acid was removed. The solutions were
finally diluted to 10 mL with ultrapure water. Atomic
absorption spectroscopy (AAS, Thermo Elemental X7,
Thermo Electron Co., Waltham, USA) was used to ana-
lyse the zinc concentration in the samples.
Statistical analysis
Statistical analysis of the obtained data was done using
SPSS version 20.0. The mean values and the standard
deviations (SDs) of each group were calculated. One-way
ANOVA statistical test was used to compare the groups
and Turkey or Dunnet’s post hoc test was used to com-
pare differences between and within groups when found.
Results
The figure above shows particle size distribution, mean
sizes and shapes of ZA (zinc-aluminium layered double
hydroxide nanocomposite coated with Tween-80), ZA-
LDH (zinc-aluminium layered double hydroxide nano-
composite), ZAL-LDH (zinc-aluminium-levodopa layered
double hydroxide nanocomposite) and ZAL (zinc-alumin-
ium-levodopa layered double hydroxide nanocomposite
coated with Tween-80).
Morbidity and mortality
An acute toxicity study using Sprague Dawley was done
with a single oral dose of ZAL and ZA of 2,000 mg/kg.
The control group (VC) received only normal saline
(100 mL/kg) body weight, each group containing seven
rats. No mortality was recorded in any of the groups up
to day 14 of observations. Behavioural toxicity signs such
as convulsion, abnormal posture, paralysis, bleeding,
vomiting, diarrhoea, breathing difficulties, restlessness
and irritation were also monitored. However, none of
the above-mentioned toxicity signs was observed in
either the treatment or control groups throughout the
14-day observational period (Table 3). Animals from
treatment and control group continued their regular
food and water intake accompanied by weight gain over
the course of the study (Figure 1). The obvious increase in
the animals’ weight was demonstrated to be significantlyt/n Mortality d/a Gross pathology l/nl
0/7 0/7
0/7 0/7
0/7 0/7
given to the rats in the treatment group as well as normal saline given to the
no death recorded and no obvious gross pathology seen in the organs
l lesion/no lesion.
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Figure 1 Bar chart showing an obvious increase in the animals’
weight in all experimental groups. There is a statistically
significant difference found between day 0 and 14 (#) and day 7
and 14 (*) (P < 0.05) in all the groups. One-way ANOVA was used
and data are expressed as mean ± SD. Average weight of rats per
group at day 0, 7 and 14.
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P value of <0.05 as tested by one-way ANOVA. When
compared between the treated and control groups, the
body weight changes were insignificant (Figure 1).
Coefficients of the brain, liver, spleen, heart and kidney
Organ weight in relation to total body weight (coefficient
of organs) of the brain, liver, spleen, heart and kidney
from the three groups was also calculated after sacrifice
(Table 4). The weights were expressed as milligrams
(wet weight of the organs in mg) to (body weight (g)].
There are no significant changes in the coefficients of
the brain, liver, spleen, heart and kidney between control
and the other two treatment groups (P > 0.05).
Biochemical analysis
Table 5 shows the results of biochemical parameters ob-
tained from the rat serum on day 14, post treatment
with nanocomposites. The enzymes, ALT, AST, ALP and
GGT, were evaluated to ensure the liver functionality.
The AST level of ZAL-treated group was shown to be
slightly higher than VC and ZA groups. The average
value for AST in ZAL-treated group was 152 ± 30 U/L
compared to 111 ± 18 and 114 ± 11 U/L from ZA and
VC, respectively. Assessment of kidney function was
done through checking changes in urea, the level of elec-
trolyte (Na+, K+ and Cl−) and creatinine, where values of
control were compared with the two treated groups.
Additionally, changes in creatine kinase between controlTable 4 Coefficients of the brain, liver, spleen, heart and righ
Group Brain mg/g Liver mg/g
ZAL 7.85 ± 0.32 39.13 ± 0.17
ZA 6.13 ± 0.29 33.90 ± 2.46
VC 6.94 ± 0.30 36.91 ± 1.77
The table shows the mean coefficient of the brain, liver, spleen, heart and right kid
control group, one-way ANOVA was used and it shows no significant difference witand nanocomposite administered groups were also
assessed. However, the difference in the level observed
in the liver, kidney and cardiac enzymes of the two
treated groups were not significantly different to that of
control animals analysed by one-way ANOVA (P > 0.05).
Histopathological evaluation
Histological examination of the liver, spleen, kidney and
brain stained with H&E stain in the control and treated
animals showed no remarkable lesions that could be attrib-
uted to the effect of a single dose of ZAL or ZA (Figures 2,
3, 4, 5 and 6). Hepatic lobular array from the treated group
and control was well maintained, central vein (CV) located
at the centre surrounded by portal triad (PT) and drained
by sinusoids (S) (Figure 2). The splenic architecture of the
high-dose treated groups showed well-maintained capsule,
clearly demarcated white and red pulp and with adjoining
trabecular all over the tissues. These histologic features
were similar to those of the vehicle control group (Figure 3).
The histology of the kidneys showed no pathologic
changes in the treated groups when compared to control
(Figure 4). The cerebral cortical layers were well delin-
eated in the brain of vehicle-administered group Figure 5C,
so is the substantia nigral region in Figure 6C. Findings in
the brain of ZAL- and ZA-treated group were remarkably
similar to those in the control group (Figures 5A, B and
6A, B). Oral administration of 2,000 mg/kg of layered hy-
droxide nanocomposite with and without levodopa does
not alter the microscopic structure of the vital organs.
The shape, size and size distribution of particles by TEM
analysis
Transmission electron microscopy (TEM) was used for
the determination of shape, size and uniformity of the
zinc-aluminium layered double hydroxide nanocomposite
(ZA-LDH), Tween-80-coated zinc-aluminium-levodopa
layered double hydroxide nanocomposite (ZAL), Tween-
80-coated zinc-aluminium layered double hydroxide nano-
composite (ZA) and zinc-aluminium-levodopa layered
double hydroxide nanocomposite (ZAL-LDH). The image
analysis software was used for the determination of size
and the size distribution of all the samples, about 80
particles were randomly chosen from a TEM image of
each individual sample. The average size of ZA-LDH
was found to be about 55 nm with narrow size distri-
bution and very visible layered shape. The levodopat kidneys after a single-dose oral exposure
Heart mg/g Spleen mg/g Kidney mg/g
3.94 ± 0.09 2.66 ± 0.09 5.22 ± 0.12
3.81 ± 0.32 2.43 ± 0.15 5.60 ± 0.33
3.75 ± 0.16 2.82 ± 0.19 4.58 ± 0.34
neys of all the groups. To compare the means of each group against the
h P > 0.05.
Table 5 Changes in biochemical parameters from serum of orally treated rats with nanocomposite
Group ALT U/L ALP U/L AST U/L CK U/L ALT/AST ratio Creat μmol/L GGT Urea Mmol/L Na Mmol/L K Mmol/L Cl Mmol/L
ZAL 66 ± 17 256 ± 18 152 ± 30 3,889 ± 71 0.43 ± 0.03 48 ± 1 <3 7 ± 1 142 ± 4 9 ± 1 102 ± 3
ZA 61 ± 6 293 ± 38 111 ± 18 3,398 ± 187 0.55 ± 0.06 47 ± 8 <3 6 ± 1 145 ± 12 8 ± 1 103 ± 10
VC 59 ± 8 312 ± 40 114 ± 11 4,410 ± 364 0.51 ± 0.02 46 ± 4 <3 6 143 ± 2 8 ± 1 101 ± 1
All data are expressed as means ± SD, and groups were compared using one-way ANOVA (n = 5) for any statistical difference between and within groups. Differences with
P < 0.05 are considered statistically significant, but none of the parameters measured were found to be significantly different compared to the control group (P > 0.05).
ALT, alanine aminotransferase; AST, aspartate aminotransferase; CK, creatine kinase; Creat, creatinine; GGT, gamma-glutamyltransferase; Na, sodium; K, potassium;
Cl, chloride.
Microscopic appearance of liver stained with H&E.
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particulate type layered shape, with an average size of
about 32 nm with narrow size distribution. The ZA, which
is LDH coated with Tween-80, had a size of about 97 nm
with narrow particle size distribution, and layered shape of
Zn/Al-LDHs was retained after Tween-80 coating. The
average size for the sample ZAL was determined to be
about 31 nm with narrow size distribution and very par-
ticulate type layered shape. Figure 7 shows the TEM mi-
crographs and particle size distribution of all of these
samples. Both ZA-LDH and ZA had a prominent layered
shape; however, they differ in their size by about 40 nm.
The levodopa intercalated nanocomposite before and after
Tween-80 showed particulate type layered shape with al-
most similar particle size distribution. Details of the sizes,
shape and average distribution were presented in Figure 7
and Table 6.
Biodistribution studies
The Tween-80-coated nanocomposite showed a wider dis-
tribution after oral administration from both repeated and
single-dose application, respectively (Figures 8 and 9).
Reasonable amount of zinc element was found in the liver,
kidney, blood and brain of the treated rats compared to
the control.
Discussion
The term ‘nano-medicine’, is a branch of nano-
biotechnology where nano-scale devices are used toBA
Figure 2 Histology of the liver tissue after H&E stain in rats. Histology
with ZAL (A), ZA (B) and vehicle control (VC) single dose each, via the ora
The hepatic lobular array is well maintained with central vein at the centre
Microscopic appearance of spleen stained with H&E.diagnose and or cure diseases [26]. These devices are gen-
erally characterized with site-specific therapeutic action
and high potential in curtailing side effects [26]. However,
achieving these objectives required a well-designed study,
so that the beneficial impact of nano-medicine is not ham-
pered by incomplete information, especially on the safety
aspect of the drug.
In acute toxicity studies, animal mortality could be ex-
plained via simple observation of clinical signs followed
by necropsy [27]. Toxicity signs like a convulsion, abnor-
mal posture, paralysis followed by abnormal necropsy
findings on the brain may be pointing to targeted brain
toxicity. Where mortality followed these symptoms/
signs, a probable cause of death will be established [27].
In this study, ZAL and ZA nanocomposite with and
without intercalated levodopa, respectively, were tested
at a limit dose based on OECD guidelines 420 [24].
However, no animals exhibited any sign of clinical tox-
icity; the treatment did not alter their feeding or water
intake. This indicated that the newly synthesized LDH-
levodopa nanocomposite may be categorized as nanode-
livery materials with no obvious clinical toxicity when
administered orally for a short period. More than three
decades ago, Clarke and Clarke described substances are
to be safe and or of low toxicity if they have LD50 of
1,000 mg/kg body weight after an oral route adminis-
tration [28].
Variation in body weight, especially when control group
is compared to treatment groups during toxicologicalC
CV
S
PT
PT
H
of the liver tissue after H&E stain (10×) in rats 2/weeks post treatment
l route. PT, portal triad; CV, central vein; H, hepatocytes; and S, sinusoid.
shown in the control (C). The same feature was also seen in A and B.
A CB
WP
RP
Figure 3 Histology of the spleen tissue in rats. Histology of the spleen tissue (10×) in rats 2/weeks post treatment with ZAL (A), ZA (B) and
vehicle control (VC) single dose each through the oral route. The red pulp (RP) and white pulp (WP) containing lymphocytes where clearly
delineated in C (control) following H&E stain. Both groups treated with ZAL (A) and with ZA (B) showed similar morphology as seen in the
control (C). Microscopic appearance of kidney stained with H&E.
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toxicity [29]. However, rats from ZAL, ZA and VC group
continued to gain weight over the 2-week study period
(Figure 1). In clinical settings, weight loss, in excess of
10% of the initial body weight, is considered scientifically
significant [30]. Among the various causes leading to
weight loss in either acute or chronic toxicity are direct
decrease in food/water intakes or secondary damages to
major organs such as the stomach, intestine, liver and kid-
ney by the substance in question, thus altering the normal
physiology [29,31]. Recently, layered double hydroxide of
magnesium-aluminium was administered to male Balb/c
mice at four different doses [32]. The changes in the body
weight pattern, demonstrated following a single-dose oral
administration of the LDH nanoparticles in these mice,
were found to be similar to the findings presented in this
study.
Another index of toxicity is the individual internal
organ weight in relation to whole animal body weight,
which we assessed through the coefficient of the liver,
kidneys, brain and spleen in this study. It is simple but
sensitive in assessing toxic substance exposure to the an-
imals. As shown in Table 4, no significant changes were
observed in the liver, kidney, spleen and brain of ZAL
and ZA group compared to VC group. Similar resultsA B
Figure 4 Histopathology of the kidney tissue (10×) 2/weeks post-exp
renal tubule. The kidney tissue was stained with H&E, showing preserved g
control group (C). Microscopic appearance of brain cortical region after H&were presented in another study, where the organoso-
matic indices of the brain, heart, intestine, kidney, liver,
lung, spleen and stomach from mice exposed to LDH
nanoparticle via the oral route were remarkably un-
affected even at 2,000 mg/kg of the nanoparticle concen-
tration [32]. However, in a related study, an inorganic
nanodelivery system of zinc oxide was shown to cause
weight loss in the heart, lung, kidneys, spleen, liver and
pancreas after oral administration [29]. The same nano-
particle caused an increase in the weight of kidney,
spleen and pancreas after intraperitoneal administration.
However, it is postulated that the toxicity potential of
the nanodelivery system could be based on route of
administration.
In the presence of liver damage due to drug toxicity or
other diseases, enzymes like alanine aminotransferase
(ALT), aspartate aminotransferase (AST), alkaline phos-
phatase (ALP) and gamma-glutamyl transpeptidase (GGT)
are usually elevated [33]. Where there is a twofold or more
of these enzymes increments, it is considered significant
[33]. The enzymes AST and ALT are elevated either due to
liver cell inflammation and subsequent necrosis or as a re-
sult of bile flow obstruction causing elevation in GGT,
ALP or both [34]. There is abandonment of macrophages
in the liver, spleen and bone marrow, allowing forG T
C
osure to ZAL (A), ZA (B) and vehicle control (C). G, glomerulus; T,
lomerular and tubular structure in A and B, similar to the finding in the
E stain.
CL
BV
N
A CB
Figure 5 Histopathology of the brain cortex in rats. Histopathology of the brain cortex (10×) in rats 2/weeks post-exposure to levodopa
nanocomposite and nanocomposite by single oral administration. ZAL (A), ZA (B) and vehicle control (C). The cortical layers (CL), neuronal cells (N)
and blood vessel (BV) are well delineated in the control group. No obvious changes were noted in the treated groups compared to the control group.
Microscopic appearance of striatum stained with H&E.
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them more vulnerable to its toxicity [34]. Previously, stud-
ies showed liver cell damage with elevated ALT and AST,
following oral administration of salts containing zinc and
zinc oxide nanoparticles [35,36]. The vast role played by
the liver in drug metabolism and the tendency for nano-
particle sequestration in the liver [37] necessitates assess-
ment of the liver functions in this study. The liver enzymes
from ZAL- and ZA-treated rats were found to be almost
similar to those of the VC (control) group. AST from ZAL
(152 ± 30) was shown to be slightly elevated compared to
what was obtained from ZA (111 ± 18) or VC (114 ± 11)
(Table 4). In hepatocellular injury or necrosis, ALT and
AST are the two crucial enzymes that may be raised [38];
but of the two enzymes, ALT is more specific and signifi-
cant. This is because of its existence mainly in the cyto-
plasm of liver cells, while AST has both mitochondrial and
cytosol type. It also exists in other tissues like the heart,
skeletal muscle, brain, liver, pancreas, kidneys, lungs and
white and red blood cells [38]. The slight differences noted
were found to be statistically insignificant (P > 0.05). The
ratio of AST to ALT (Table 5) in the treated groups was
statistically not different from control. Assessing AST/ALT
ratio can further give clues to what causes liver damage
where it occurs [39]. Thus, oral ingestion of ZAL and ZA
at 2,000 mg/kg in Sprague Dawley rats did not induce any
significant liver damage biochemically.
Damage to the kidneys or dehydration can be detected
through blood biochemical analysis, looking at urea,A B
Figure 6 Histopathology of the striatum in rats. Histopathology of the
vehicle control (C). The morphology of the substantia nigra (SN) is well ou
the SN structure shown in the two treated groups (A and B).electrolytes and creatinine in order to assess changes to
the renal system. There was no elevation in serum urea,
electrolytes (Na+, K+, Cl−) or creatinine in the two
treated groups as compared to the vehicle control group.
Statistically, there is no any significant difference be-
tween the groups (Table 4). Body exposure to noxious
drugs as well as other toxins can easily lead to nephro-
toxicity, usually treatable and reversible, but can pro-
gress to a permanent renal damage and its consequent
outcome [40]. None of these changes associated with
renal impairment were observed after 2,000 mg/kg of
the ZAL and ZA nanocomposite were given to the rats
via the oral route. The normal urea and electrolyte re-
sults further attested to the said regular water intake of
the treated and control groups, which was observed
within the observation period. This is because severe de-
hydration will alter the urea and some electrolyte levels,
notably Na+ and K+ [41]. Movement of water and elec-
trolyte inside and outside the cells will be deranged as
well [41]. Nephrotoxicity was reported in 5 mg/kg of ti-
tanium dioxide nanoparticles of different sizes adminis-
tered to animals via the oral route [37]. In this study,
2,000 mg/kg ZAL and ZA administered to the rats did
not cause any change in water intake nor do they dam-
age the renal system of the animals.
On gross examination of internal organs of rats from
ZAL, ZA and VC groups, no lesions or anomalies were
found. This complemented the increase in weight, absence
of morbidity, mortality and excellent clinical status thatSN
C
striatum (10×) in rats 2/weeks post-exposure to ZAL (A), ZA (B) and
tlined from the brain of the control group (C), similar preservation of
Figure 7 TEM images of the nanocomposite before and after intercalation with levodopa.
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and 4).
Zinc distribution in the treated and untreated animals of
both single and repeated dose study groups follows the re-
ported normal pattern of zinc distribution in the body
[42]. The liver was shown to accumulate more zinc ion
than the spleen, kidney, brain and blood. The distribution
of zinc in Figure 8 is showing higher concentration in the
liver of the treated rats than the control, also higher con-
centration in the kidney, spleen, brain and blood samples
of the treated rats than their control counterparts. Figure 9
which is the distribution analysis from the repeated dose
study showed higher concentrations of the zinc ion in the
blood, brain and kidney of the treated rats compared to
the control group. The spleen and the liver on theTable 6 Particle sizes, shape and distribution pattern
Sample ZA-LDH ZAL-LDH
Shape Layered type Particulate type laye
Average size 55 nm 32 nm
Particle size distribution Narrow Narrow
Table showing particle sizes, shape and distribution for both intercalated and un-in
Tween-80. ZA-LDH (zinc-aluminium layered double hydroxide nanocomposite), ZAL
(zinc-aluminium-levodopa layered double hydroxide nanocomposite coated with Tw
with Tween-80).contrary demonstrated slightly lower concentration in the
treated samples compared to the control. In the past,
inductile couple plasma (ICP) was used to analyse the
concentration Mg metal after intravenous injection of
anti-cancer LDH nanocomposite to a group of mice [43].
There, liver tissue shows consistent higher concentration
of the metal compared to other organs tested; the kidney
on the other hand showed increase concentration of Mg
metal with increasing time, likely as a result renal excre-
tion after circulation. The concentration of zinc in the kid-
neys of treated rats in this study is higher than the control
group. This is more so in the 500 mg/kg repeated-dose
treated group attributable to higher concentration used in
the treated group. The concentration is higher than the
control but less than that seen in the single-dose study asZAL ZA
red Layered type Very narrow layered particulate type
31 nm 97 nm
Narrow Narrow
tercalated zinc-aluminium nanocomposite before and after coating with
-LDH (zinc-aluminium-levodopa layered double hydroxide nanocomposite), ZAL
een-80), ZA (zinc-aluminium layered double hydroxide nanocomposite coated
05
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Figure 8 Graph showing nanocomposite distribution in tissues
of rats 14 days after single oral dose administration.. Zinc
distribution in rats after single dose of Tween-80-coated
zinc-aluminium-levodopa layered double hydroxide nanocomposite
(ZAL), tissue collected 14 days after treatment with 2,000 mg/kg (X)
and 100 mL/kg of PBS (Z). No significant difference found between
control and treated group in any of tissues analysed P > 0.05.
Kura et al. Nanoscale Research Letters  (2015) 10:105 Page 10 of 11the samples were collected 14 days after the treatment.
Interestingly, the blood sample of the nanocomposite-
treated rats demonstrated zinc metal accumulation more
so in the 5 mg/kg repeated-dose group, collected about
24 h after the last dose. The indication here is the wider
distribution of the LDH nanocomposite after oral admin-
istration of different concentrations and the delivery af-
fecting many organs including the brain. Two things likely
responsible for this wider distribution and even delivery of
this nanocomposite to the brain are the particle sizes
(55 nm) and the surface coating with Tween-80.0
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Figure 9 Graph showing nanocomposite distribution after
repeated doses in a 28-day oral toxicity study. Graph showing
nanocomposite distribution in tissues of rats after repeated doses in
a 28-day oral toxicity study. Zinc distribution in rats after repeated
dose of Tween-80-coated zinc-aluminium-levodopa layered double
hydroxide nanocomposite ( ZAL) over 28-day period. B = 500 mg/kg
of ZAL, D = 5 mg/kg of ZAL, J = 100 mL/kg of PBS (control group).
No significant difference found between control and treated group
in any of tissues analysed P > 0.05.Conclusion
In this study, the acute toxicity potential of zinc-aluminium
nanocomposite intercalated with levodopa (ZAL) via
oral route at 2,000 mg/kg is evaluated in whole animals.
Neither the intercalated hybrid (ZAL) nor the un-
intercalated nano-hybrid showed any clinical, biochemical
or pathological perturbation after 14 days of treatment.
The AST/ALT ration of the two treated groups is not sig-
nificantly different from control. The distribution of the
nanocomposite after single and repeated oral doses
covered most of the body organs including the brain.
However, there is the need for further toxicity study, em-
phasizing on chronic and gene toxicity assessment and fo-
cusing more on possible liver and renal damage.
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